Eligible patients with complete resection of stage III melanoma and a screening MRI of the brain, made within 12 weeks after resection and before adjuvant treatment (programmed cell death protein 1 inhibitors, dabrafenib–trametinib), available between 1 August 2018 and 1 January 2021, were included. Here, PDCD1 is linked to melanoma.